| Full Name | Thomas Kizy |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 13 Years |
| Location | 329 Columbia St, Algonac, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457637506 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 57.020167 (Ohio) | Secondary |
| 207Q00000X | Family Medicine | 4301106396 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension River District Hospital | East china, MI | Hospital |
| Entity Name | Seton Health Corporation Of Southeastern Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598177065 PECOS PAC ID: 2567689540 Enrollment ID: O20140814002590 |
News Archive
diaDexus, Inc., a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced the commercial launch of its CE-marked PLAC Test for Lp-PLA(2) Activity in Europe.
ATCC today announced the introduction of its new SARS-CoV-2 External Control Kit for clinical laboratories and test manufacturers.
Music therapy can reduce psychological stress among pregnant women, according to research just published in a special complementary and alternative therapy medicine issue of the UK-based Journal of Clinical Nursing.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.
› Verified 2 days ago
| Entity Name | Thomas Kizy Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457726770 PECOS PAC ID: 4284937244 Enrollment ID: O20160125002475 |
News Archive
diaDexus, Inc., a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced the commercial launch of its CE-marked PLAC Test for Lp-PLA(2) Activity in Europe.
ATCC today announced the introduction of its new SARS-CoV-2 External Control Kit for clinical laboratories and test manufacturers.
Music therapy can reduce psychological stress among pregnant women, according to research just published in a special complementary and alternative therapy medicine issue of the UK-based Journal of Clinical Nursing.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Kizy, MD Po Box 477, Algonac, MI 48001-0477 Ph: (810) 720-5715 | Thomas Kizy, MD 329 Columbia St, Algonac, MI 48001 Ph: (810) 671-3190 |
News Archive
diaDexus, Inc., a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced the commercial launch of its CE-marked PLAC Test for Lp-PLA(2) Activity in Europe.
ATCC today announced the introduction of its new SARS-CoV-2 External Control Kit for clinical laboratories and test manufacturers.
Music therapy can reduce psychological stress among pregnant women, according to research just published in a special complementary and alternative therapy medicine issue of the UK-based Journal of Clinical Nursing.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.
› Verified 2 days ago
Dr. David T. Hindy, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 555 Saint Clair River Dr, Algonac, MI 48001 Phone: 810-794-4982 Fax: 810-794-4407 | |
Jason R Bortnem, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 555 Saint Clair River Dr, Algonac, MI 48001 Phone: 810-794-4917 Fax: 810-794-4407 | |
Sidra Sindhu, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 555 Saint Clair River Dr, Algonac, MI 48001 Phone: 810-794-4917 | |
Dr. Julia Anastazja Krakowska, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 555 Saint Clair River Dr, Algonac, MI 48001 Phone: 810-794-4917 | |
Dr. Shelia Renee Stephens, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 555 Saint Clair River Dr, Algonac, MI 48001 Phone: 810-794-4982 Fax: 810-794-4407 | |
Dr. Michael R. Priebe, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 555 Saint Clair River Dr, Algonac, MI 48001 Phone: 810-794-4982 Fax: 810-794-4407 |